3月7日 - ** 生物制药公司CorMedix CRMD.O股价盘前上涨3.6%至9.83美元
** Leerink Partners开始覆盖CRMD，给予 "跑赢大盘 "评级，目标价18美元，较上一交易日收盘价上涨89.6%。
** 券商称该公司的医疗设备 DefenCath 是预防导管相关血流感染的 "重大进步"，可将感染率降低高达 70
** DefenCath 用于预防接受血液透析的肾衰竭患者的导管感染，导管是医疗程序中使用的一种细管。
** 经纪公司预计，到 2028 年，DefenCath 的销售额将达到 3.7 亿美元。
** 指出该公司拥有 "稳健的商业执行力"，并与 60% 的美国透析诊所建立了合作关系，这将推动 "DefenCath 的销量大幅增长"。
** 2024 年股价增长一倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.